

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

Spark Blue(TM) 550 anti-human CD14

RRID:AB_2832724

Type: Antibody

Proper Citation

BioLegend Cat# 367148, RRID:AB_2832724

Antibody Information

URL: http://antibodyregistry.org/AB_2832724

Proper Citation: BioLegend Cat# 367148, RRID:AB_2832724

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Spark Blue(TM) 550 anti-human CD14

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: Clone 63D3

Antibody ID: AB_2832724

Vendor: BioLegend

Catalog Number: 367148

Alternative Catalog Numbers: 367147

Record Creation Time: 20250819T223715+0000

Record Last Update: 20250820T024625+0000

Ratings and Alerts

No rating or validation information has been found for Spark Blue(TM) 550 anti-human CD14.

No alerts have been found for Spark Blue(TM) 550 anti-human CD14.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Saidoune F, et al. (2025) Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains. The Journal of experimental medicine, 222(7).

Marciello I, et al. (2025) Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry. STAR protocols, 6(2), 103775.

Osorio JC, et al. (2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer cell.

de Homdedeu M, et al. (2023) Mycobacterium manresensis induces trained immunity in vitro. iScience, 26(6), 106873.

Szymula A, et al. (2023) Macrophages drive KSHV B cell latency. Cell reports, 42(7), 112767.

Haubner S, et al. (2023) Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer cell, 41(11), 1871.

Middelburg J, et al. (2023) The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. Cell reports, 42(12), 113516.

Lozano-Rodríguez R, et al. (2022) Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell reports, 38(2), 110235.

Mulder K, et al. (2021) Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity, 54(8), 1883.

Szabo PA, et al. (2021) Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity, 54(4), 797.